Novo Nordisk is halving the US list price of its most popular weight-loss drug as the Danish drugmaker struggles to compete with rival Eli Lilly in the obesity market.
Novo said on Tuesday that the wholesale US price of Wegovy would be cut by 50 per cent from January 2027. Its diabetes drug Ozempic will be reduced by 35 per cent. The new list price for each drug will be $675 a month and will apply to Wegovy injections and tablets. The wholesale price for Lilly’s weight-loss drug Zepbound is more than $1,000 a month.
The lower prices would increase the customer base, said Jamey Millar, executive vice-president of Novo’s US operations.
您已阅读29%（639字），剩余71%（1538字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。